A personalized approach to managing patients with uterine fibroids

Levakov С.A., Budanov P.V., Zairatyants O.V., Movtaeva Kh.R., Azadova G.Ya., Levakova S.E.

1) I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia, Moscow, Russia; 2) A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia
A change in the socialization of society, a tendency toward late pregnancy planning, and an increase in the incidence of uterine fibroids among reproductive-aged women determine the relevance of treatment for this disease and take on social significance.
Objective. To evaluate the comparative efficacy of mifepristone (Ginestril), a selective progesterone receptor modulator (SPRM) (Esmya), and a gonadotropin-releasing hormone GnRH agonist (Buserelin Depot) in the treatment of women with uterine fibroids and internal endometriosis.
Subjects and methods. A total of 150 women diagnosed with uterine fibroids and internal endometriosis of the corpus uteri were selected. The inclusion criteria were the presence of symptoms of uterine fibroids, refusal of surgical treatment, a desire to maintain reproductive function, and preparation for planned pregnancy. All the patients were randomly divided into three groups of 50 people each according to a prescribed drug (mifepristone, ulipristal acetate, GnRH agonist) and for the convenience of statistical analysis. Therapy was prescribed for 3 months. All the examinees were reproductive-aged.
Results. When mifepristone and ulipristal were used, there was the highest frequency of devascularization of myomatous nodules, as evidenced by Doppler study. Twenty-nine of 36 patients receiving mifepristone had myomas transformed from proliferating to simple. The ulipristal and GnRH-agonist groups had similar data (28/35 and 26/36, respectively). After 3 months of treatment, the largest number of cases without active peri- and intranodular blood flow in the area of a myomatous nodule were recorded in the mifepristone group (62%; n = 31). Six months after the start of the study (3 months after completion of therapy), the uterine volume was re-estimated. At this stage, 6 (4%) women who became pregnant were excluded from the study. The adverse reactions of Ginestril use included weight gain (by less than 3% of the baseline weight in one (2%) patient), headache, and weakness (in two (4%) patients). Patients with liver and kidney dysfunction were excluded before ulipristal acetate was administered. The use of Esmya was accompanied by reversible endometrial thickening by more than 16 mm (12%) after its treatment cessation, hot flashes (6%), psychoemotional disorders (12%), headache (12%), and acne (12%). The administration of Buserelin Depot resulted in headache, psychoemotional disorders (14%), decreased libido (12%), and insomnia (12%).
Conclusion. Drug therapy aimed at eliminating the symptoms of uterine fibroids is an effective tool for organ sparing, preparation for pregnancy, and surgical treatment. Mifepristone most actively converts the clinical variant of proliferating fibroids into a simple one. The highest safety profile and the possibility of dose adjustment is an important aspect of choosing mifepristone. The prescription of ulipristal requires mandatory additional examination. This drug is comparable to mifepristone in the degree and rate of a decrease in the size of myomatous nodules. The GnRH agonist more markedly reduces the size of the uterus in fibroids concurrent with internal endometriosis of the corpus uteri. The use of the GnRH agonist is associated with the higher incidence of side effects compared with ulipristal and mifepristone.


uterine fibroids
drug treatment
GnRH agonist


  1. Сидорова И.С., ред. Миома матки. М.: МИА, 2002; 256 с. [Sidorova I.S., ed. Uterine fibroids. M .: MIA, 2002; 256 p. (in Russian)]
  2. Радзинский В.Е., Архипова М.П. Миома матки: проблемы и перспективы начала века. Медицинский совет. 2014; (9): 30–33. [Radzinskiy V.E., Arkhipova M.P. Uterine fibroids: problems and prospects at the turn of the century. Medical Council. 2014; (9): 30–33. (In Russ.)]. https://doi.org/10.21518/2079-701X-2014-9-30-33
  3. Сидорова И.С., Агеев М.Б. Клинико-морфологические особенности простой и пролиферирующей миомы матки. Российский вестник акушера-гинеколога. 2013;13(6): 34–38.[Sidorova IS, Ageev MB. The clinical and morphological features of simple and proliferating uterine myoma. Rossiyskiy vestnik akushera-ginekologa/Russian Bulletin of Obstetrician-Gynecologist. 2013; 13(6): 34–38.(in Russian)]
  4. Khan Z., Stewart E.A. Benign uterine diseases. Yen & Jaffe’s Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management: Eighth Edition. Elsevier Inc., 2018. pp. 643–661.e15. doi:10.1016/B978-0-323-47912-7.00026-3
  5. Levy B.S. Management of uterine fibroids. Acta Obstet Gynecol Scand. 2008; 87(8): 812–23. doi: 10.1080/00016340802146912.
  6. Stewart E.A. Uterine fibroids and evidence-based medicine – not an oxymoron.N. Engl. J. Med. 2012; 366: 471–3. doi: 10.1056/NEJMe1114043
  7. Zimmermann A., Bernuit D., Gerlinger C., et al. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. BMC Women’s Health. 2012; 12: 6. doi: 10.1186/1472-6874-12-6
  8. Bougie O., Suen M.W., Pudwell J., et al.. Evaluating the Prevalence of Regret With the Decision to Proceed With a Hysterectomy in Women Younger than Age 35. J Obstet Gynaecol Can. 2019; pii: S1701-2163(19)30732-7. doi: 10.1016/j.jogc.2019.08.006.
  9. Основные показатели здоровья матери и ребенка, деятельность службы охраны детства и родовспоможения в Российской Федерации. https://static0.rosminzdrav.ru/system/attachments/attaches/000/046/523/original/13_Основные_показатели_здоровья_матери_и_ребенка_деятельность_службы_охраны_детства_и_родовспоможения_2018.doc?1564572095[Osnovnye pokazateli zdorov’ja materi i rebenka, dejatel’nost’ sluzhby ohrany detstva i rodovspomozhenija v Rossijskoj Federacii. https://static0.rosminzdrav.ru/system/attachments/attaches/000/046/523/original/13_Osnovnye_pokazateli_zdorov’ja_materi_i_rebenka_dejatel’nost’_sluzhby_ohrany_detstva_i_rodovspomozhenija_2018.doc?1564572095.(in Russ.)]
  10. Адамян Л.В., Зайратьянц О.В., Тихомиров А.Л. и др. Антипролиферативное и проапоптотическое действие селективного модулятора рецепторов прогестерона улипристала на лейомиому матки in vivo. Проблемы репродукции. 2014; 3: 25–28.[Adamian L.V., Zaĭrat’iants O.V., Tikhomirov A.L., Manukhin I.B., Opalenov K.V., Kazenashev V.V., Alieva T.D. Antiproliferative and proapoptotic effects of the selective progesterone receptor modulator ulipristal on uterine leiomyoma in vivo. Problemy reproduktsii/Russian Journal of Human Reproduction. 2014; (3): 41–44.(in Russian)]
  11. Демура Т.А., Ревазова З.В., Коган Е.А., Адамян Л.В. Молекулярные механизмы и морфологические проявления редукции лейомиомы под действием селективных модуляторов прогестероновых рецепторов. Архив патологии. 2017; 3:19–26.[Demura T.A., Revazova Z.V., Kogan E.A., Adamyan L.V. The molecular mechanisms and morphological manifestations of leiomyoma reduction induced by selective progesterone receptor modulators. Arkhiv Patologii/Archive of Pathology. 2017; 79(3): 19–26. doi: 10.17116/patol201779319-26
  12. Леваков С.А., Зайратьянц О.В., Боровкова Е.И. Эффективность и безопасность применения селективных модуляторов прогестероновых рецепторов в терапии больных простой и пролиферирующей миомой матки. Акушерство и гинекология. 2015; 3: 94–99.[Levakov S.A., Zairatyants O.V., Borovkova E.I. Efficacy and safety of progesterone receptor inhibitors used in the therapy of patients with simple and proliferating uterine myoma. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2015; 3: 94–99.(in Russian)]
  13. Horak P., Mara M., Dundr P., et al. Effect of a selective progesterone receptor modulator on induction of apoptosis in uterine fibroids in vivo. Int J Endocrinol. 2012; 2012:436174. doi: 10.1155/2012/436174.
  14. Тихомиров А.Л. Миома, патогенетическое обоснование органосохраняющего лечения. М.: Медицина, 2013. 319 с.[Tikhomirov A.L. Myoma, pathogenetic substantiation of organ-preserving treatment. M.: Medicine, 2013; 319 p.(in Russian)
  15. Адамян Л.В., Зайратьянц О.В., Манухин И.Б., и соавт. Подавление ангиогенеза и продукции факторов роста в сочетании с индукцией активности металлопротеиназ в лейомиомах матки после курса терапии улипристалом. Проблемы репродукции. 2014; 4: 28–34.[Adamian L.V., Sonova M.M., Shamugiia N.M. The experience of uterine fibroids treatment with selective progesterone-receptor modulator. Problemy reproduktsii/Russian Journal of Human Reproduction. 2014; 4: 28–34.(in Russian)].
  16. Lethaby A., Vollenhoven B., Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst Rev. 2001; (2): CD000547. doi: 10.1002/14651858.CD000547
  17. Sayed G.H., Zakhera M.S., El-Nashar S.A., Shaaban M.M. A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroidrelated menorrhagia // Int J Gynaecol Obstet. 2011; 112: 126–130. doi: 10.1016/j.ijgo.2010.08.009.
  18. Адамян Л.В., Козаченко А.В., Ревазова З.В. Новые подходы к медикаментозному лечению симптомной миомы матки. Проблемы репродукции. 2013; 3: 21–23.[Adamian L.V., Kozachenko A.V., Revazova Z.V. New approaches to the medical treatment of symptomatic uterine fibroid (areview). Problemy reproduktsii/Russian Journal of Human Reproduction. 2013; (3): 22–24.(in Russian)]
  19. Donnez J., Donnez O., Dolmans M.M. With the advent of selective progesterone receptor modulators, what is the place of myoma surgery in current practice? Fertil Steril. 2014; 102(3): 640–8. doi: 10.1016/j.fertnstert.2014.06.04
  20. Courtoy G.E., Donnez J., Marbaix E., Dolmans M.-M. In vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment. Fertil Steril. 2015; 104(2): 426–34.e1. doi: 10.1016/j.fertnstert.2015.04.025
  21. Fiscella J., Bonfiglio T., Winters P., et al. Distinguishing features of endometrial pathology after exposure to the progesterone receptor modulator mifepristone. Hum. Pathol. 2011; 42: 947–53.
  22. Леваков С.А., Зайратьянц О.В., Мовтаева Х.Р. Миома матки: Учебное пособие. М.: Группа МДВ, 2019. 168 с.[Levakov S.A., Zairatyants O.V., Movtaeva H.R. Uterine fibroids: Textbook. M .: MDV Group, 2019.168 p.(in Russian)]
  23. Зайратьянц О.В., Манухин И.Б., Тихомиров А.Л., Казенашев В.В., Опаленов К.В., Барсанова Т.Г., Алиева Т.Д. Новый вид обратимых морфологических изменений эндометрия (РАЕС – progesterone receptor modulator associated endometrial changes) при терапии лейомиом матки. Клиническая и экспериментальная морфология. 2013; 4: 4–12.[Zayratyants O.V., Manukhin I.B., Tikhomirov A.L., Kazenashev V.V., Opalenov K.V., Barsanovа T.G., Aliyeva T.D.New kind of reversible morphological changes of endometrium (PAEC – Progesterone Receptor Modulator Associated Endometrial Changes) in the therapy of uterine leiomyomata. Klinicheskaja i jeksperimental’naja morfologija. 2013; 4: 4–12.(in Russian)].
  24. Hiller O., Lichte A., Oberpichler A., Kocourek A., Tschesche H. Matrix metalloproteinases collagenase-2, macrophage elastase, collagenase-3, and membrane type 1-matrix metalloproteinase impair clotting by degradation of fibrinogen and factor XII. J. Biol. Chem. 2000; 275: 8–13. doi: 10.1074/jbc.M001836200
  25. Biglia N., et al. Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids. Drug Des Devel Ther.2014; 8: 285–92. doi: 10.2147/DDDT.S54565
  26. Brunn J., Block U., Ruf G., et al. Volumetrie der Schilddrusenlappen mittels Realtime-Sonogrpahie. Dtsch Med Wochenschr. 1981; 106: 1338–40.

Received 11.11.2019

Accepted 29.11.2019

About the Authors

Levakov Sergey A., MD, Professor, head of the Department of obstetrics and gynecology, Institute of clinical medicine, Moscow State medical university. I. M. Sechenova Ministry of health of Russia (Sechenov University). E-mail: levakoff@yandex.ru
Address: 119991, Moscow, Trubetskaya str. 8, p. 2.
Pavel V. Budanov, MD, Professor, Department of obstetrics and gynecology, Institute of clinical medicine, Federal STATE Autonomous educational institution of First Moscow state medical University them. I. M. Sechenova Ministry of health of Russia (Sechenov University).
Address: 119991, Moscow, Trubetskaya str. 8, p. 2.
Oleg V. Zayratyants, MD, Professor head of the Department of pathological anatomy of the Moscow state medical University. A. I. Evdokimova “ Ministry of health of Russia, chief specialist-expert on pathological anatomy of Roszdravnadzor in the Central Federal district of the Russian Federation.
Address: 127473, Moscow, Delegatskaya St., 20, p. 1
Khadijat R. Movtaeva applicant of the Department of obstetrics and gynecology of the Institute of clinical medicine of the Moscow state university I. M. Sechenova Ministry of Health of Russia (Sechenov University).
Address: 119991, Moscow, Trubetskaya str. 8, p. 2
Gyallar Ya. Azadova, post-graduate student of the Department of obstetrics and gynecology Of the Institute of clinical medicine. I. M. Sechenova Ministry of Health Of Russia (Sechenov University).
Address: 119991, Moscow, Trubetskaya str. 8, p. 2
Svetlana E. Levakova, applicant of the Department of obstetrics and gynecology of the Institute of clinical medicine of the Moscow state University. I. M. Sechenova Ministry of Health Of Russia (Sechenov University).
Address: 119991, Moscow, Trubetskaya str. 8, p. 2

For citation: Levakov S.A., Budanov P.V., Zairatyants O.V., Movtaeva Kh.R., Azadova G.Ya., Levakova S.E. A personalized approach to managing patients with uterine fibroids.
Akusherstvo i Ginekologiya/ Obstetrics and gynecology. 2019; 12:174-82. (In Russian).

Similar Articles

By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.